Overview

* Iridex ( IRIX ) Q3 revenue grows 8% yr/yr, driven by glaucoma probe and Pascal system sales

* Operating expenses decreased 12% yr/yr due to cost reduction measures

* Net loss for Q3 narrows to $1.6 mln from $1.9 mln yr/yr

Outlook

* Iridex expects to achieve cash flow breakeven in Q4 2025

* Company aims for positive adjusted EBITDA for full year 2025

* Iridex ( IRIX ) plans to sustain cash flow positivity going forward

Result Drivers

* GLAUCOMA PROBE SALES - Revenue growth driven by increased sales of Cyclo G6 glaucoma probes

* COST REDUCTION - Operating expenses decreased 12% due to cost-cutting measures

* INVENTORY WRITE-DOWN - Gross margin impacted by a one-time inventory write-down

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $12.50

Revenue mln

Q3 EPS -$0.09

Q3 Net -$1.60

Income mln

Q3 Gross $4 mln

Profit

Q3 $5.40

Operatin mln

g

Expenses

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)